Mazdutide approved in US in 2025
2
Ṁ45Dec 31
38%
chance
1D
1W
1M
ALL
Mazdutide, a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics and Eli Lilly, has shown promising results in weight management. It received approval from China's NMPA in June 2025. This market predicts whether the FDA will approve mazdutide for weight management in the U.S. before December 22, 2025. Resolution will be based on official FDA announcements.
Get Ṁ1,000 play money
Related questions
Related questions
FDA approves YCT-529 male birth control pill before 2035?
35% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?
62% chance
💊Will INS018_055 be FDA-approved by 2030?
48% chance
Any myostatin inhibitor FDA approved by 2027
63% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
7% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?
19% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
62% chance
Will a drug to be used by most healthy adults be approved by 2043 year end?
70% chance
When will retatrutide receive full FDA approval, making it legal to prescribe in the United States?
Will a drug that didn't go through human clinical trials be approved by 2034?
27% chance